Abstract:Autophagy is a catabolic process that regulates the lysosomal turnover of damaged proteins and organelles in order to maintain cellular homeostasis. Dysregulation of autophagy is often observed in lung cancer. Kinase inhibitors have proved successful in the clinic. The fact that uncoordinated (Unc) 51-like kinase (Ulk1) is the only conserved serine/threonine kinase in the autophagy cascade makes it a very attractive target for therapeutic development. Up-regulation of Ulk1 has been shown to promote cell survival of several cancer cell lines. Moreover, overexpression of Ulk1 has been shown to be negatively correlated with the prognosis of several types of human cancer. However, the role of Ulk1 in NSCLC is largely unknown. We evaluated Ulk1 expression levels in human normal lung epithelial cell line BEAS-2B and five NSCLC cell lines, A549, H460, H1299, H292 and HCC827. We analyzed the correlation between Ulk1 expression levels and the prognosis of NSCLC patients. We evaluated the effect of SBI0206965 alone or in combination with cisplatin on cell proliferation, apoptosis and autophagy in two human NSCLC cell lines, A549 and H460. Cell proliferation of untreated or drug-treated cells was measured by CCK8 assay. Percentage of apoptotic cells was measured using PE-conjugated Annexin V with a flow cytometer. Autophagy was determined by conversion of LC3I to LC3II and p62 degradation using Western blot. Ulk1 is overexpressed in NSCLC cell lines and negatively correlated with the prognosis of NSCLC patients. The inhibition of Ulk1 by a selective inhibitor, SBI0206965, blocks the proliferation of NSCLC cells and induces apoptosis. SBI0206965 treatment augments the efficacy of cisplatin to kill NSCLC cells by inhibiting cisplatin induced cell protective autophagy. SBI0206965 can also destabilize Bcl2/Bclxl to promote cisplatin induced apoptosis in NSCLC cell lines. Our results suggest that the inhibition of Ulk1 may be a promising strategy for the treatment of NSCLC. SBI0206965 may be a promising agent for the treatment of NSCLC by modulating autophagy and apoptosis pathways. Furthermore, the combination of SBI0206965 with classical chemotherapy agents represents a promising therapeutic strategy that warrants further clinical evaluation in NSCLC.

Targeting SPHK1/PBX1 Axis Induced Cell Cycle Arrest in Non-Small Cell Lung Cancer

Cancer Therapy : Preclinical Sphingosine Kinase-1 Enhances Resistance to Apoptosis through Activation of PI 3 K / Akt / NFk B Pathway in Human Non – Small Cell Lung Cancer

SCYL1-BP1 affects cell cycle arrest in human hepatocellular carcinoma cells via Cyclin F and RRM2.

Data from Sphingosine Kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NF-κB Pathway in Human Non–Small Cell Lung Cancer

Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.

Liriopesides B Induces Apoptosis and Cell Cycle Arrest in Human Non‑small Cell Lung Cancer Cells.

P3.02c-004 SBI0206965, a Novel Inhibitor of Ulk1, Suppresses Non-Small Cell Lung Cancer Cell Growth Via Modulating Both Autophagy and Apoptosis Pathways: Topic: Targeted Therapy

SPHK1 Promotes HNSCC Immune Evasion by Regulating the MMP1-PD-L1 Axis

Combined Effects on Leukemia Cell Growth by Targeting Sphingosine Kinase 1 and Sirtuin 1 Signaling.

Increased SPK1 expression promotes cell growth by activating the ERK1/2 signaling in non-small-cell lung cancer.

PRC1 Promotes Cell Proliferation and Cell Cycle Progression by Regulating P21/p27-Prb Family Molecules and FAK-paxillin Pathway in Non-Small Cell Lung Cancer.

SphK1 functions downstream of IGF-1 to modulate IGF-1-induced EMT, migration and paclitaxel resistance of A549 cells: A preliminary in vitro study

Preclinical Pharmacodynamic Evaluation of Drug Candidate Sklb-178 in the Treatment of Non-Small Cell Lung Cancer

Thrombospondin‐1 mimic peptide PKHB1 induced endoplasmic reticulum stress‐mediated but CD47‐independent apoptosis in non‐small cell lung cancer

The P70s6k Specific Inhibitor PF-4708671 Impedes Non-Small Cell Lung Cancer Growth

SBI0206965, a Novel Inhibitor of Ulk1, Suppresses Non-Small Cell Lung Cancer Cell Growth by Modulating Both Autophagy and Apoptosis Pathways.

The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy

Targeted inhibition of the PI3K/AKT/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer

Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC

Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer

Sphingosine Kinase 1 Signaling in Breast Cancer: A Potential Target to Tackle Breast Cancer Stem Cells